Pulse Biosciences (NASDAQ:PLSE) Shares Gap Up – What’s Next?

Pulse Biosciences, Inc. (NASDAQ:PLSE) shares gapped up before the market opened on Tuesday . The stock had previously closed at $17.40, but opened at $17.87. Pulse Biosciences shares last traded at $18.04, with a volume of 23,965 shares.

Analysts Set New Price Targets

Separately, StockNews.com raised Pulse Biosciences to a “sell” rating in a research note on Tuesday.

Pulse Biosciences Trading Up 5.5 %

The company’s 50 day simple moving average is $17.93 and its 200-day simple moving average is $16.66.

Pulse Biosciences (NASDAQ:PLSE) last issued its quarterly earnings results on Wednesday, October 30th. The company reported ($0.21) earnings per share for the quarter. During the same period in the prior year, the firm earned ($0.19) earnings per share.

Insider Buying and Selling at Pulse Biosciences

In related news, Director Robert W. Duggan bought 55,256 shares of the stock in a transaction that occurred on Friday, December 13th. The stock was purchased at an average cost of $17.18 per share, for a total transaction of $949,298.08. Following the completion of the acquisition, the director now owns 42,328,717 shares in the company, valued at $727,207,358.06. This trade represents a 0.13 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Burke Thomas Barrett sold 50,000 shares of the stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $17.42, for a total transaction of $871,000.00. Following the transaction, the chief executive officer now directly owns 63,172 shares in the company, valued at approximately $1,100,456.24. This represents a 44.18 % decrease in their position. The disclosure for this sale can be found here. 71.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Pulse Biosciences

Large investors have recently modified their holdings of the stock. Quest Partners LLC acquired a new position in shares of Pulse Biosciences during the second quarter worth $91,000. Rhumbline Advisers increased its stake in Pulse Biosciences by 6.7% during the 2nd quarter. Rhumbline Advisers now owns 25,729 shares of the company’s stock worth $288,000 after buying an additional 1,608 shares during the period. Franklin Resources Inc. acquired a new position in Pulse Biosciences in the 3rd quarter worth $378,000. Creative Planning lifted its holdings in Pulse Biosciences by 113.9% in the 3rd quarter. Creative Planning now owns 21,910 shares of the company’s stock worth $384,000 after buying an additional 11,667 shares in the last quarter. Finally, Barclays PLC boosted its position in Pulse Biosciences by 361.4% in the 3rd quarter. Barclays PLC now owns 30,306 shares of the company’s stock valued at $530,000 after buying an additional 23,738 shares during the last quarter. Institutional investors and hedge funds own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.